Castle Biosciences (CSTL) Non-Current Debt (2018 - 2026)

Castle Biosciences (CSTL) has 6 years of Non-Current Debt data on file, last reported at $8.4 million in Q1 2026.

• Quarterly Non-Current Debt fell 5.85% year-over-year to $8.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.4 million (down 5.85% YoY) and the FY2025 annual result came in at $9.6 million, down 1.08% from the prior year.
• Non-Current Debt slipped to $8.4 million in Q1 2026 per CSTL's latest filing, from $9.6 million in the prior quarter.
• The five-year high for Non-Current Debt was $10.0 million in Q3 2025, with the low at $8.1 million in Q2 2025.
• Average Non-Current Debt over 3 years is $9.4 million, with a median of $9.7 million recorded in 2024.
• The widest YoY moves for Non-Current Debt: up 0.34% in 2025, down 19.1% in 2025.
• Castle Biosciences' Non-Current Debt stood at $9.7 million in 2024, then dropped by 1.08% to $9.6 million in 2025, then declined by 12.87% to $8.4 million in 2026.
• Business Quant data shows CSTL's Non-Current Debt at $8.4 million in Q1 2026, $9.6 million in Q4 2025, and $10.0 million in Q3 2025.